Safety and influence of a novel extract of fenugreek on healthy young women: a randomized, double-blinded, placebo-controlled study

Khanna, Aman; Thomas, Jestin; John, Febi; Maliakel, Balu; Krishnakumar, I. M.

doi:10.1186/s40816-021-00296-y

Clinical Phytoscience

International Journal of Phytomedicine and Phytotherapy

Table 4 Hematological and biochemical parameters in FHE and placebo

From: Safety and influence of a novel extract of fenugreek on healthy young women: a randomized, double-blinded, placebo-controlled study

Parameters	Groups	Baseline	End of Study	P-value
Hemoglobin (g/dL)	Placebo FHE	15.3 ± 0.3 14.1 ± 0.4	14.8 ± 0.3 14.5 ± 0.4	0.075
Total leukocyte count (cells/cumm)	Placebo FHE	6072 ± 304.5 6195 ± 318.1	6178 ± 321.5 6305 ± 345.2	0.549
Total RBC count (million/cumm)	Placebo FHE	4.3 ± 0.12 4.5 ± 0.14	4.6 ± 0.11 4.4 ± 0.10	0.788
PC (lakhs/cumm)	Placebo FHE	2.5 ± 0.32 2.4 ± 0.3	2.3 ± 0.28 2.2 ± 0.25	0.325
PCV (%)	Placebo FHE	38.5 ± 1.5 34.3 ± 1.2	35.4 ± 1.1 32.3 ± 1.2	0.333
MCH (pg)	Placebo FHE	30.7 ± 1.4 32.3 ± 1.3	32.9 ± 1.5 31.8 ± 1.3	0.385
MCHC (g/dL)	Placebo FHE	85.5 ± 2.7 87.2 ± 2.5	82.1 ± 2.3 85.3 ± 2.4	0.323
MCV (fL)	Placebo FHE	92.7 ± 2.5 94.8 ± 2.8	95.1 ± 2.3 96.4 ± 2.5	0.961
Neutrophils (%)	Placebo FHE	52.7 ± 3.1 50.8 ± 3.0	55.1 ± 4.0 52.4 ± 3.7	0.439
Lymphocytes (%)	Placebo FHE	40.7 ± 2.0 42.2 ± 2.1	38.4 ± 2.2 36.9 ± 2.0	0.662
Eosinophil’s (%)	Placebo FHE	4.2 ± 0.65 4.0 ± 0.72	4.1 ± 0.62 3.8 ± 0.55	0.795
Monocytes (%)	Placebo FHE	3.2 ± 0.65 3.1 ± 0.62	3.5 ± 0.52 3.3 ± 0.54	0.980
ESR (mm/hr)	Placebo FHE	10.4 ± 1.0 10.6 ± 1.2	8.4 ± 0.92 8.8 ± 1.1	0.342
Triglycerides	Placebo FHE	126.3 ± 4.5 129.5 ± 4.8	136.2 ± 5.2 132.5 ± 5.4	0.773
Total Cholesterol	Placebo FHE	192.4 ± 7.5 189.7 ± 7.2	185.7 ± 6.5 182.2 ± 6.2	0.642
HDL Cholesterol	Placebo FHE	40.2 ± 2.2 43.5 ± 2.5	42.7 ± 2.5 45.5 ± 2.5	0.698
LDL Cholesterol	Placebo FHE	152.8 ± 4.2 148.7 ± 4.0	158.2 ± 4.2 152.7 ± 4.8	0.380
VLDL Cholesterol	Placebo FHE	28.7 ± 7.2 26.1 ± 8.1	25.7 ± 6.8 27.2 ± 7.7	0.298
SGOT (U/L)	Placebo FHE	23.1 ± 4.2 26.7 ± 4.8	25.4 ± 4.9 27.3 ± 5.2	0.822
SGPT (U/L)	Placebo FHE	35.2 ± 7.2 38.5 ± 7.6	32.7 ± 6.7 35.3 ± 6.5	0.717
Alkaline phosphatase	Placebo FHE	55.7 ± 7.0 62.8 ± 7.8	52.7 ± 7.2 55.3 ± 7.4	0.353

RBC- Red blood cells, PC- Platelet count, PCV- Packed cell volume, MCH- Mean corpuscular hemoglobin, MCHC- Mean corpuscular hemoglobin concentration, MCV- Mean corpuscular volume, ESR- Erythrocyte sedimentation rate, HDL- High-density lipoprotein, LDL- Low-density lipoprotein, VLDL- Very low-density lipoprotein, SGOT- Serum glutamate oxaloacetate transferase, SGPT- Serum glutamate pyruvate transferase. A general linear model with adjustments for baseline values were used to predict marginal means (95% CI) for each outcome variable. Values are expressed as mean ± SD. P ≤ 0.05 considered as statistically significant with baseline

Back to article page